

---

# Contents

## Part I Cancer Prevention and Health Politics

<b>1 Do We Make Optimal Use of the Potential of Cancer Prevention?</b>	<b>3</b>
Peter Greenwald and Barbara K. Dunn	
1.1 Introduction	4
1.2 Lifestyle Interventions	4
1.3 Medical Interventions	7
1.4 The Changing Landscape of Clinical Studies	7
1.5 Prevention Clinical Trials	9
1.6 Biomarkers for Cancer Prevention	11
1.7 Systems Biology	13
1.8 Future Directions for Attaining Optimal Impact in Cancer Prevention	14
References	15
<b>2 Predictors of Successful Cancer Prevention Programs</b>	<b>19</b>
Franz Porzsolt, Anita Kirner, and Robert M. Kaplan	
2.1 Introduction	19
2.2 Methods	20
2.3 Results	20
2.3.1 Quality of Prevention Programs	20
2.3.2 Recommended Prevention Programs	24
2.3.3 Critical Appraisal of Traditional Selection Criteria	25
2.3.4 Incidence in Primary and Secondary Prevention	26
2.4 Discussion	27
References	29

<b>3</b>	<b>Cancer Prevention in the Developing World: Mission Impossible?</b> .....	33
	Franco Cavalli	
3.1	A Changing Pattern .....	33
3.2	A Possible Roadmap .....	35
3.3	A Provisional Conclusion .....	37
	References .....	38
<b>4</b>	<b>Is Cancer Prevention Ever Going to Be Profitable?</b> .....	41
	Thomas D. Szucs and Konstantin J. Dedes	
4.1	Introduction .....	41
4.2	What Will Be the Economic Future of Cancer Care? .....	42
4.3	How Do We Determine “Value for Money”? .....	42
4.3.1	Types of Formal Economic Evaluations .....	45
4.3.2	Applying Cost-Effectiveness Evaluations .....	46
4.4	So Will Cancer Prevention Ever Be Profitable? .....	46
	References .....	47
 <b>Part II Cancer Prevention: The Scientific-Epidemiological Base</b>		
<b>5</b>	<b>Energy Metabolism, Cancer Risk, and Cancer Prevention</b> .....	51
	Michael Pollak	
	References .....	53
<b>6</b>	<b>Promises and Limitations of Biomarkers</b> .....	55
	David F. Ransohoff	
6.1	Promise Versus Product .....	55
6.2	Threats to Validity from Chance and Bias .....	55
6.3	Addressing Current Problems .....	56
6.3.1	Every Study Should Be Reliable .....	56
6.3.2	Drug Research Versus Marker Research .....	56
6.3.3	Role of Specimens .....	57
6.3.4	Shortcuts: By Using Already-Collected Specimens .....	57
6.4	Conclusion .....	58
	References .....	58
 <b>Part III Cancer Prevention, Tobacco and Nutrition</b>		
<b>7</b>	<b>The EPIC Study: An Update</b> .....	63
	Paolo Vineis and Elio Riboli	
7.1	The EPIC Study Design .....	63
7.1.2	Exposure Variables .....	64
7.1.3	Follow-Up and Case Ascertainment .....	64
7.1.4	Biological Samples .....	65

7.2	Recent Find ings on Diet and Biomarkers .....	65
7.2.1	Fibres, Meat Intake and Colorectal Cancer.....	65
7.2.2	Cancer, Hormones and BMI .....	65
	References.....	68
<b>8</b>	<b>Anti-angiogenic Properties of Chemopreventive Drugs:</b>	
	<b>Fenretinide as a Prototype .....</b>	<b>71</b>
	Ilaria Sogno, Roberta Venè, Cristina Sapienza, Nicoletta Ferrari, Francesca Tosetti, and Adriana Albini	
8.1	Molecular Regulators of Angiogenesis as Drug Targets for Chemoprevention.....	71
8.2	Angioprevention: When Cancer Chemoprevention Meets Angiogenesis .....	72
8.3	Retinoids and 4HPR as Angiopreventive Molecules .....	73
	References.....	74
<b>9</b>	<b>Retinoids and Breast Cancer Prevention .....</b>	<b>77</b>
	Bernardo Bonanni and Matteo Lazzeroni	
9.1	Introduction.....	77
9.2	Clinical Trials.....	78
9.3	Fenretinide and Ovarian Cancer .....	80
9.4	Conclusions and Future Perspectives.....	80
	References.....	81
<b>Part IV Cancer Prevention, Genetics and Vaccines</b>		
<b>10</b>	<b>Cancer Prevention by Vaccination Against Hepatitis B .....</b>	<b>85</b>
	Mei-Hwei Chang	
10.1	Introduction.....	85
10.2	Cancer Prevention by Vaccination .....	86
10.2.1	Advantage of Cancer Prevention by Vaccination.....	86
10.3	Chronic Hepatitis B Virus Infection and Hepatocellular Carcinoma.....	87
10.4	Strategies to Prevent Viral Hepatitis B-Associated Hepatocellular Carcinoma .....	87
10.4.1	Primary Prevention by Immunoprophylaxis .....	87
10.4.2	Treatment of Viral Hepatitis/Cirrhosis.....	87
10.4.3	Chemoprevention.....	87
10.4.4	Liver Transplantation for End-Stage Cirrhosis .....	88
10.5	Cancer Prevention by Hepatitis B Vaccination .....	88
10.6	Why Should the Hepatitis B Vaccine Be Given at Birth to Prevent Cancer? .....	88
10.7	Hepatitis B Immunoprophylaxis Program .....	89
10.8	Impact of Universal Hepatitis B Immunization on Chronic Infection .....	90

10.9	Demonstration of the Efficacy of Cancer Prevention by Hepatitis B Vaccination.....	90
10.10	Problems in Preventing Liver Cancer by Vaccination.....	90
10.10.1	Inadequate Resources .....	91
10.10.2	Ignorance or Poor Compliance Due to Anxiety to the Safety of Vaccine .....	91
10.10.3	Vaccine Failure or Nonresponders .....	91
10.10.4	No Effective Vaccine Available .....	92
10.11	Conclusions and Future Prospects .....	92
10.11.1	Hepatoma Control.....	92
10.11.2	Implication to the Control of Other Cancers .....	92
	References.....	92

## **Part V Cancer Prevention and Target Organs I: Breast Cancer**

<b>11</b>	<b>Energy Restriction for Breast Cancer Prevention.....</b>	<b>97</b>
	Anthony Howell, Mary Chapman, and Michelle Harvie	
11.1	Introduction.....	97
11.2	Risk Factors for Breast Cancer .....	98
11.3	Effect of Weight and Weight Gain and Exercise Deficiency on Breast Cancer Risk.....	98
11.4	Mechanism of Weight Gain and Exercise Deficiency on Risk.....	99
11.5	Chronic Energy Restriction Reduces Cancer Risk .....	99
11.6	Intermittent Energy Restriction Also Reduces Breast Cancer Risk .....	100
11.7	Mechanism of the Effect of CER and IER .....	100
11.8	Energy Restriction Mimetic Agents.....	101
11.9	Inhibitors of Glycolysis.....	102
11.10	Inhibitors of Lipid Synthesis .....	103
11.11	Activation of AMP-Activated Protein Kinase.....	104
11.12	Stimulation of Mitochondrial Activity and Fat Oxidation .....	104
11.13	Activation of SIRT1 .....	104
	Summary and Conclusions .....	105
	References.....	105
<b>12</b>	<b>The Use of Tamoxifen and Raloxifene for the Prevention of Breast Cancer .....</b>	<b>113</b>
	D. Lawrence Wickerham, Joseph P. Costantino, Victor G. Vogel, Walter M. Cronin, Reena S. Cecchini, Leslie G. Ford, and Norman Wolmark	
12.1	Introduction.....	114
12.2	The Study of Tamoxifen and Raloxifene .....	114
12.3	Results.....	115
12.3.1	Invasive Breast Cancer.....	115

12.3.2	Noninvasive Breast Cancer .....	116
12.3.3	Other Secondary Endpoints .....	116
12.4	Discussion.....	117
	References.....	118
<b>13</b>	<b>Prevention of ER-Negative Breast Cancer .....</b>	<b>121</b>
	Yuxin Li and Powel H. Brown	
13.1	SERMs and Aromatase Inhibitors .....	122
13.2	Novel Agents for the Prevention of ER-Negative Breast Cancer.....	123
13.3	Retinoids .....	124
13.4	Vitamin D Receptor .....	127
13.5	EGFR/Tyrosine Kinase Inhibitors.....	127
13.6	COX-2 Inhibitors .....	129
13.7	Statins .....	130
13.8	Combination Chemoprevention .....	130
13.9	Conclusion .....	131
	Acknowledgement .....	131
	References.....	132
<b>14</b>	<b>Exogenous and Endogenous Hormones, Mammographic Density and Breast Cancer Risk: Can Mammographic Density Be Considered an Intermediate Marker of Risk? .....</b>	<b>135</b>
	Susen Becker and Rudolf Kaaks	
14.1	Introduction.....	135
14.2	General Determinants and Correlates of Mammographic Density .....	137
14.3	Sex Steroid Hormones and Breast Density.....	137
14.3.1	Postmenopausal Hormone Replacement Therapy .....	137
14.3.2	Endogenous Sex Hormones .....	138
14.4	Selective Estrogen Receptor Modulators.....	142
14.5	Aromatase Inhibitors .....	143
14.6	Gonadotropin-Releasing Hormone Agonists.....	144
14.7	IGF-I and Its Binding Proteins .....	145
14.8	Prolactin.....	146
14.9	Discussion.....	149
	References.....	150
<b>Part VI</b>	<b>Cancer Prevention and Target Organs II: Cancer of the Digestive Tract</b>	
<b>15</b>	<b>Chemoprevention of Oesophageal Cancer and the AspECT Trial.....</b>	<b>161</b>
	Debasish Das, Andrew P. Chilton, and Janusz A. Jankowski	
15.1	Introduction.....	161
15.2	Barrett's Oesophagus .....	162

15.3	Need for Chemoprevention Approach Rather Than Surveillance .....	162
15.4	The AspECT Trial .....	163
15.5	Trials Related to AspECT .....	164
15.6	The Evidence Base for Using Aspirin and Esomeprazole .....	165
15.6.1	Aspirin .....	165
15.6.2	Esomeprazole .....	165
15.7	Conclusion .....	167
	References .....	167

## **Part VII Cancer Prevention and Target Organs III: Prostate Cancer**

<b>16</b>	<b>Review of Diagnostic Markers for Prostate Cancer .....</b>	<b>173</b>
	Fritz H. Schröder	
16.1	Characteristics of PSA-Driven Screening .....	174
16.1.1	PSA and Cancer Aggressiveness .....	175
16.2	How to Improve on PSA in the Detection of Prostate Cancer? .....	176
16.2.1	PSA Use in Men Less Than 50 Years Old .....	176
16.3	Selective Detection of Aggressive Prostate Cancer .....	178
16.3.1	PSA Velocity .....	179
16.4	Needs and Expected Future Developments .....	179
16.5	Conclusions .....	180
	References .....	180
<b>17</b>	<b>Selenium and Vitamin E Cancer Prevention Trial: A Nutrient Approach to Prostate Cancer Prevention .....</b>	<b>183</b>
	Barbara K. Dunn, Anne Ryan, and Leslie G. Ford	
17.1	Introduction .....	183
17.1.1	A Preventive Approach to the Problem of Prostate Cancer .....	183
17.1.2	SELECT: Selection of Study Interventions .....	184
17.2	SELECT: Study Design .....	186
17.2.1	Study Objectives .....	186
17.2.2	Selection of Study Agents .....	186
17.2.3	Study Cohort .....	187
17.2.4	Study Design .....	187
17.2.5	Statistical Considerations .....	188
17.2.6	Evaluation of Prostate Cancer Endpoint .....	189
17.2.7	SELECT in Contrast to PCPT .....	189
17.2.8	Ancillary Studies .....	189
17.3	Study Implementation .....	190
17.4	Future Challenges in the Conduct of SELECT .....	190
	References .....	191

<b>18</b>	<b>Prostate Cancer Prevention by Short-Term Anti-androgens: The Rationale Behind Design of Pilot Studies .....</b>	<b>195</b>
	Tim Oliver, Attila Lorincz, and Jack Cuzick	
18.1	Introduction.....	195
18.2	Modern Evidence of a Contributory Role for Sexually Acquired Infection to Causation of Prostate Cancer But Lack of Specificity of Organism.....	196
18.3	Modern Ideas on the Role of Inflammation as Causative of Malignant Transformation and Its Relevance to Prostate Cancer .....	197
18.4	PSA Screening and Impact on Over-Diagnosis of Prostate Cancer.....	198
18.5	Evidence of Harm from Prostate Biopsy .....	199
18.6	Lack of Evidence of Major Therapeutic Gain from Current Approaches to Radical Treatment of Prostate Cancer .....	199
18.7	Possible New Approaches to Chemo-prevention of Prostate Cancer.....	200
18.8	Choice of Patient Populations for Chemo-prevention Studies.....	200
18.8.1	Patients with Low-Grade Prostate Cancer Volunteering for Surveillance Protocols.....	200
18.8.2	Patients with Persistent PSA Elevation After a Negative Biopsy Developing Prostate Cancer .....	201
18.8.3	Patients with STDs.....	201
18.8.4	Patients with Male Factor Infertility .....	201
18.9	Conclusion .....	202
	References.....	202

## **Part VIII Cancer Prevention: Metabolic Aspects**

<b>19</b>	<b>Anti-angiogenic Activity of a Novel Class of Chemopreventive Compounds: Oleanic Acid Terpenoids .....</b>	<b>209</b>
	Ilaria Sogno, Nicola Vannini, Gireca Lorusso, Rosaria Cammarota, Douglas M. Noonan, Luca Generoso, Michael B. Sporn, and Adriana Albini	
19.1	Introduction.....	210
19.2	Angioprevention and Anti-angiogenic Therapy .....	210
19.3	Triterpenoids: New Promising Angiogenesis Regulators .....	211
	References.....	212

**Part IX Aspirin and NSAIDs in Cancer Prevention:  
Attempts at an International Consensus**

<b>20 Pharmacologic Effects of NSAIDs and Implications for the Risks and Benefits of Long-Term Prophylactic Use of Aspirin to Prevent Cancer .....</b>	<b>215</b>
Michael J. Thun and Bonny Blackard	
20.1 Introduction.....	215
20.2 Risk–Benefit Considerations .....	219
20.3 Conclusions.....	220
References.....	220
<b>21 Aspirin and NSAIDs for the Prevention of Colorectal Cancer .....</b>	<b>223</b>
John A. Baron	
21.1 Introduction.....	223
21.2 Colorectal Neoplasia: Observational Studies .....	224
21.3 Clinical Trial Data: Sporadic Colorectal Neoplasia.....	225
21.4 Special Populations .....	226
References.....	227
<b>22 Aspirin and Cancer Risk: A Summary Review to 2007 .....</b>	<b>231</b>
Cristina Bosetti, Silvano Gallus, and Carlo La Vecchia	
22.1 Introduction.....	231
22.2 Materials and Methods .....	231
22.3 Results.....	232
22.3.1 Colon and Rectal Cancer .....	232
22.3.2 Other Digestive Tract Cancers .....	238
22.3.3 Lung Cancer.....	243
22.3.4 Breast and Ovarian Cancers.....	243
22.3.5 Prostate Cancer .....	244
22.3.6 Bladder and Kidney Cancers .....	244
22.3.7 Lymphatic and Haematopoietic Cancers .....	244
22.4 Discussion.....	245
References.....	245



Cancer Prevention II

Senn, H.-J.; Kapp, U.; Otto, F. (Eds.)

2009, XX, 252 p. 28 illus., 14 illus. in color., Hardcover

ISBN: 978-3-540-69296-6